Adaptive Biotechnologies Corporation (ADPT)
NASDAQ
Closed
Aug 25, 2026
Day's Range
25.2352 wk Range
12.00Overview - ADPT - Adaptive Biotechnologies Corporation
Key Statistics
Valuation
Enterprise Value
4.22B
P/E (Trailing)
‪-67.30‬
P/E (Forward)
‪-140.69‬
PEG Ratio
‪-1.43‬
Price / Sales (TTM)
‪13.46‬
Price / Book
‪28.94‬
EV / EBITDA
‪-197.96‬
Profitability
Profit Margin
‪-20.72%‬
Operating Margin
‪-22.04%‬
Return on Assets
‪-4.11%‬
Return on Equity
‪-38.75%‬
Ownership
Shares Outstanding
159.59M
Float
125.46M
Short % of Shares Outstanding
‪9.93%‬
Held by Insiders
‪1.30%‬
Held by Institutions
‪99.25%‬
Price stats
Beta
‪2.08‬
50-Day Avg
‪22.01‬
200-Day Avg
‪17.17‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪$ 25.07‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ADPT - Adaptive Biotechnologies Corporation
Peers - ADPT - Adaptive Biotechnologies Corporation
Peer Comparison
Compared with companies in Diagnostics & Research listed on NASDAQ.
- ADPTNASDAQAdaptive Biotechnologies Corporation4.14BMarket Cap+51.25%52-week change-66.64P/E (Trailing)‪-20.72%‬Profit Margin
- NTRANASDAQNATERA INC (Common Stock) – ticker 45E47.23BMarket Cap+50.52%52-week change-220.14P/E (Trailing)‪-7.10%‬Profit Margin
- IDXXNASDAQIDEXX Laboratories, Inc.44.07BMarket Cap-14.69%52-week change39.06P/E (Trailing)‪25.03%‬Profit Margin
- ILMNNASDAQIllumina, Inc.33.70BMarket Cap+55.77%52-week change41.01P/E (Trailing)‪18.33%‬Profit Margin
- GHNASDAQGuardant Health Inc.22.13BMarket Cap+61.54%52-week change-49.67P/E (Trailing)‪-38.32%‬Profit Margin
- MEDPNASDAQMedpace Holdings Inc.17.13BMarket Cap+23.58%52-week change36.41P/E (Trailing)‪17.66%‬Profit Margin
- ICICLRNASDAQICON plc13.38BMarket Cap-0.84%52-week change264.97P/E (Trailing)‪0.32%‬Profit Margin
Profile Summary - ADPT - Adaptive Biotechnologies Corporation
About
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for diagnosing and treating various diseases. The company's core offering is its immunosequencing platform, which uses proprietary chemistry, computational biology, and machine learning to…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
